文献速递淋巴瘤白血病

伊布替尼联合纳武利尤单抗治疗复发非霍奇金淋巴瘤或慢性淋巴细胞白血病的安全性与活性:1/2a期研究

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
PubMed 文献 · Lancet Haematol · 2019-01-11

这项在澳大利亚、以色列、波兰、西班牙、土耳其和美国21家医院开展的两部分开放标签1/2a期研究,评估伊布替尼联合纳武利尤单抗在复发或难治性B细胞恶性肿瘤患者中的安全性与活性;141例可分析患者中,高风险慢性淋巴细胞白血病/小淋巴细胞淋巴瘤总体缓解22/36(61%),滤泡性淋巴瘤13/40(33%),弥漫大B细胞淋巴瘤16/45(36%),Richter转化13/20(65%)。

要点

  • 伊布替尼联合纳武利尤单抗的总体安全性可接受。
  • Richter转化患者缓解率65%(13/20),作者认为有前景并支持进一步临床评估。
  • 3-4级中性粒细胞减少28%(40/141),3-4级贫血23%(32/141)。

核心结论

  • 伊布替尼联合纳武利尤单抗具有可接受的安全性,初步活性与单药伊布替尼在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、滤泡性淋巴瘤和弥漫大B细胞淋巴瘤中报告的活性相似。
  • Richter转化患者的临床缓解有前景,支持进一步临床评估。

研究设计与样本

  • 两部分、开放标签、1/2a期研究,在澳大利亚、以色列、波兰、西班牙、土耳其和美国的21家医院开展。
  • A部分(剂量递增)主要目的是评估每日口服伊布替尼(420 mg或560 mg)联合静脉纳武利尤单抗(3 mg/kg,每2周一次)的安全性,以确定II期推荐剂量,采用改良毒性概率区间设计进行剂量优化。
  • B部分(扩展期)主要目的是确定联合方案在四个队列中的初步活性(达到总体缓解的患者比例):复发或难治性高风险慢性淋巴细胞白血病或小淋巴细胞淋巴瘤(del17p或del11q)、滤泡性淋巴瘤、弥漫大B细胞淋巴瘤和Richter转化。
  • 2015年3月12日至2017年4月11日入组144例患者,3例在接收研究治疗前死亡,141例纳入分析(A部分14例,B部分127例)。
  • 所有接受至少一剂治疗的受试者纳入主要分析,按疾病队列进行分析;试验注册号ClinicalTrials.gov NCT02329847,试验进行中。

主要发现

  • A部分420 mg剂量组弥漫大B细胞淋巴瘤队列报告1例剂量限制性毒性(3级高胆红素血症),5天后缓解。
  • 总体缓解:高风险慢性淋巴细胞白血病或小淋巴细胞淋巴瘤22/36(61%),滤泡性淋巴瘤13/40(33%),弥漫大B细胞淋巴瘤16/45(36%),Richter转化13/20(65%)。
  • 最常见全等级不良事件:腹泻47/141(33%)、中性粒细胞减少44/141(31%)、乏力37/141(26%)。
  • 11/141(8%)患者发生导致死亡的不良事件,均未报告为药物相关。
  • 最常见3-4级不良事件:中性粒细胞减少40/141(28%)和贫血32/141(23%);3-4级中性粒细胞减少发生率从弥漫大B细胞淋巴瘤的8/45(18%)到慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的19/36(53%),3-4级贫血发生率从滤泡性淋巴瘤的5/40(13%)到Richter转化的7/20(35%)。

临床怎么用

  • 作者认为,伊布替尼联合纳武利尤单抗具有可接受的安全性,初步活性与单药伊布替尼在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、滤泡性淋巴瘤和弥漫大B细胞淋巴瘤中报告的活性相似。
  • 作者认为,Richter转化患者的临床缓解有前景,支持进一步临床评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety and activity of ibrutinib in combination with nivolumab in patients with relapsed or refractory B-cell malignant diseases. METHODS: We did a two-part, open-label, phase 1/2a study at 21 hospitals in Australia, Israel, Poland, Spain, Turkey, and the USA. The primary objective of part A (dose escalation) was to assess the safety of daily oral ibrutinib (420 mg or 560 mg) in combination with intravenous nivolumab (3 mg/kg every 2 weeks) to ascertain a recommended phase 2 dose in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymphoma, or diffuse large B-cell lymphoma. Dose optimisation was investigated using a modified toxicity probability interval design. The primary objective of the part B expansion phase was to establish the preliminary activity (the proportion of patients who achieved an overall response) of the combination of ibrutinib and nivolumab in four cohorts: relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymphoma, diffuse large B-cell lymphoma, and Richter's transformation. All participants who received at least one dose of treatment were included in the primary analysis and analyses were done by disease cohort. This trial is registered with ClinicalTrials.gov, number NCT02329847. The trial is ongoing. FINDINGS: Between March 12, 2015, and April 11, 2017, 144 patients were enrolled in the study. Three patients died before receiving study treatment; thus, 141 patients were included in the analysis, 14 in part A and 127 in part B. One dose-limiting toxicity (grade 3 hyperbilirubinaemia) was reported at the 420 mg dose in the diffuse large B-cell lymphoma cohort, which resolved after 5 days. The combination of ibrutinib and nivolumab led to overall responses in 22 (61%) of 36 patients with high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma, 13 (33%) of 40 patients with follicular lymphoma, 16 (36%) of 45 patients with diffuse large B-cell lymphoma, and 13 (65%) of 20 patients with Richter's transformation. The most common all-grade adverse events were diarrhoea (47 [33%] of 141 patients), neutropenia (44 [31%]), and fatigue (37 [26%]). 11 (8%) of 141 patients had adverse events leading to death; none were reported as drug-related. The most common grade 3-4 adverse events were neutropenia (40 [28%] of 141 patients) and anaemia (32 [23%]). The incidence of grade 3-4 neutropenia ranged from eight (18%) of 45 patients with diffuse large B-cell lymphoma to 19 (53%) of 36 patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma; incidence of grade 3-4 anaemia ranged from five (13%) of 40 patients with follicular lymphoma to seven (35%) of 20 patients with Richter's transformation. The most common serious adverse events included anaemia (six [4%] of 141 patients) and pneumonia (five [4%]). The most common grade 3-4 immune-related adverse events were rash (11 [8%] of 141 patients) and increased alanine aminotransferase (three [2%]). INTERPRETATION: The combination of ibrutinib and nivolumab had an acceptable safety profile and preliminary activity was similar to that reported with single-agent ibrutinib in chronic lymphocytic leukaemia or small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma. The clinical response in patients with Richter's transformation was promising and supports further clinical assessment. FUNDING: Janssen R&D.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Lancet Haematol. 2019. PMID: 30642819. doi:10.1016/S2352-3026(18)30217-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。